"Designing Growth Strategies is in our DNA"
Dengue is an expeditious emerging pandemic-prone viral infection worldwide. Dengue largely affects the poor urban areas, suburbs, and countryside but also affects the tropical and subtropical regions. Dengue is a mosquito-borne disease caused by a family of Flaviviridae virus and spread through a vector, Aedes mosquitoes causing a severe flu-like illness, and sometimes leading to lethal complications. Symptoms of dengue include high fever accompanied by severe headache, nausea, vomiting, muscle & joint pain and rashes.
Currently, there is a lack of specific treatment for dengue, but early detection and access to proper medical care reduces the fatality rates. For milder forms, prevention of dehydration, medications including painkillers, non-steroidal anti-inflammatory drugs, and other interventions are provided. Acetaminophen is used to reduce pain and fever in dengue patients.
According to World Health Organization (WHO), increase in dengue cases is being reported in regions of Western Pacific, Africa, and America in 2019, when compared to 2017-2018, emphasizing the need for novel therapy. Pharmaceutical companies, along with various research institutes, are focusing on studying and developing novel vaccines for the treatment of dengue. For instance; TDV, which is being studied by Takeda Pharmaceutical Company Limited is currently in phase 3 clinical trials for the study of safety and immunogenicity in dengue patients of non-endemic areas.
To know how our report can help streamline your business, Speak to Analyst
At present, around 54% of the pipeline candidates for dengue are in the phase-1 clinical stage. Maximum studies are sponsored by research institutes.
The report on ‘Dengue – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Dengue. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Dengue.
The report on ‘Dengue – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.